Rocket reels in Renovacor for $53 million

20 September 2022

In an all-stock deal valued at around $53 million, Rocket Pharmaceuticals (Nasdaq: RCKT) is to acquire fellow US biotech firm Renovacor (NYSE: RCOR).

Rocket is advancing a pipeline of genetic therapies for rare childhood disorders with high unmet need and has announced positive pediatric safety data from its Phase I RP-A501 Danon Disease program.

"The broadest platform in the field to address these devastating rare cardiac diseases"In the Renovac all-stock deal valued at around $53 million, Rocket Pharmaceuticals is to acquire fellow US biotech firm Renovacor. and is seeking to deliver innovative precision therapies to improve the lives of patients and families battling genetically-driven cardiovascular and mechanistically-related diseases.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK